ライフサイエンスコーパス: antiparasitic

1 ee molecules show promise for development as antiparasitic (25 and 29) and anti-inflammatory (32) age

2 antimicrobial, insecticidal, larvicidal and antiparasitic activities and toxicity of T. zygis essent

3 These high antiparasitic activities encourage us to propose these c

4 l profile and antioxidant, antimicrobial and antiparasitic activities of the hydroalcoholic extract o

5 tenuisol derivatives were screened for their antiparasitic activities, which provide a preliminary st

6 nt of biological probes and drugs with novel antiparasitic activities.

7 antimicrobial, insecticidal, larvicidal and antiparasitic activities.

8 protease (K(i) = 0.6 pM) and a submicromolar antiparasitic activity (EC(50) = 0.67 muM), thus represe

9 (k(second) = 8811 x 10(5)) coupled to a good antiparasitic activity (EC(50) = 3.6 muM), while vinyl k

10 Alkynyl substituents improved antiparasitic activity against resistant strains, likely

11 C50 of 2.2 muM, against TbFolD and displayed antiparasitic activity against T. brucei (IC50 49 muM).

12 35 muM; LmPTR1 IC(50) = 1.9 muM) and low muM antiparasitic activity against T. brucei.

13 arasite egress and invasion and shows strong antiparasitic activity against T. gondii The same compou

14 ive antitoxin immunity, suggesting that both antiparasitic activity and antidiarrheal activity can be

15 ened a collection of 85 compounds with known antiparasitic activity and identified 59 compounds that

16 ynthesis of 44 compounds with broad-spectrum antiparasitic activity and minimal toxicity against Tryp

17 Apicidin's antiparasitic activity appears to be due to low nanomola

18 against human cells while retaining a potent antiparasitic activity both in vitro and in vivo and cle

19 Expression of molecules with antiparasitic activity by genetically transformed symbio

20 We assessed antiparasitic activity by testing for the presence of T.

21 um complexes of clotrimazole (CTZ) with high antiparasitic activity have been synthesized, cis,fac-[R

22 A subset of inhibitors also displayed potent antiparasitic activity in a Toxoplasma gondii model.

23 acemic version of 15a, also displayed superb antiparasitic activity in a Toxoplasma gondii strain tha

24 It has stronger antiparasitic activity in cellular experiments, cures th

25 Despite showing antiparasitic activity in these in vivo studies, the opt

26 We report the preparation and antiparasitic activity in vitro and in vivo of a series

27 This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and

28 xcellent ligand efficiency (LE), and display antiparasitic activity in vitro.

29 ion of iron by desferrioxamine abrogates the antiparasitic activity of artemisinins and corresponding

30 gs demonstrate for the first time the direct antiparasitic activity of CCL20 against an enteric proto

31 e of the human parasite Brugia malayi to the antiparasitic activity of cyclosporin A (CsA) may arise

32 s against TbPTR1 were able to potentiate the antiparasitic activity of methotrexate when evaluated in

33 al parasites has not been described, and the antiparasitic activity of NO produced by B. bovis-stimul

34 act of a comprehensive set of factors on the antiparasitic activity of Norwegian conifers to identify

35 sible for the highly potent trypanocidal and antiparasitic activity of the monoenone curcuminoids.

36 Medicinal chemistry was then used to improve antiparasitic activity of the top hits from the screen.

37 y reported a prodrug approach to improve the antiparasitic activity of this inhibitor by converting t

38 r shortly after immunization, the protective antiparasitic activity of this T cell response also is l

39 phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causat

40 ion of their mechanism of action or superior antiparasitic activity relative to analogs with the orig

41 submicromolar, rapid-killing, pan-life cycle antiparasitic activity showed that all had acquired muta

42 oxolanes would exhibit Fe(II) reactivity and antiparasitic activity similar to that achieved with can

43 pared and evaluated for in vitro and in vivo antiparasitic activity that led a few hits especially nu

44 nto proof-of-concept translation of in vitro antiparasitic activity to in vivo efficacy.

45 e CD8(+) T cells are not capable of exerting antiparasitic activity unless previously primed by paras

46 Antiparasitic activity was determined using in vitro ass

47 idone derivatives were synthesized and their antiparasitic activity was evaluated.

48 ng and varied N-alkyl substitutions enhanced antiparasitic activity, metabolic stability, and in vivo

49 TDI-8414 showed nanomolar antiparasitic activity, no toxicity to HepG2 cells, high

50 c subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to

51 a 2,4-disubstituted azaindole that had good antiparasitic activity, selectivity, and predicted brain

52 ors were also evaluated and found to possess antiparasitic activity, suggesting that HDA is an attrac

53 Biological and biophysical data show that antiparasitic activity, toxicity, and DNA binding of thi

54 molecule, fosinoprilat, is essential for its antiparasitic activity.

55 l blood stages were used to assay multistage antiparasitic activity.

56 phnia magna indicated ecotoxicity lower than antiparasitic activity.

57 matodes and in insects to be a target of the antiparasitic agent avermectin.

58 atal and 1 surviving, treated with the novel antiparasitic agent miltefosine.

59 Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity

60 demonstrate that ivermectin, an FDA-approved antiparasitic agent, is effective at inhibiting replicat

61 the unexpected synergistic combination of an antiparasitic agent, pentamidine, and a phenothiazine an

62 n antioxidant, and/or benzonidazole (BZ), an antiparasitic agent.

63 ulated by ivermectin (IVM), a broad-spectrum antiparasitic agent.

64 s, suggesting their further investigation as antiparasitic agents against T. b. rhodesiense.

65 d for development of potent, mechanism-based antiparasitic agents against these diseases.

66 In addition, we found that FDA approved antiparasitic agents belonging to the 'azole' family als

67 the field of anticancer, antitubercular and antiparasitic agents containing nitro groups, along with

68 e the way for the development of more potent antiparasitic agents in the near future.

69 n diseases as antibacterial, antioxidant and antiparasitic agents is reviewed for the first time.

70 (CD), caused by Trypanosoma cruzi parasites, antiparasitic agents that successfully clear T. cruzi do

71 al role in the design of inhibitors, such as antiparasitic agents, or adenine-based substrates.

72 To further investigate their utility as antiparasitic agents, we compare the cellular effects of

73 In search of antiparasitic agents, we here identify arylmethylamino s

74 importance of plant essential oils as novel antiparasitic agents.

75 tractive target for the development of novel antiparasitic agents.

76 ssible antiviral, anticancer, antifungal and antiparasitic agents.

77 ore constitute a logical source of potential antiparasitic agents.

78 e these compounds as promising candidates as antiparasitic agents.

79 n issues that challenge their development as antiparasitic agents.

80 rypanosoma brucei FolD (TbFolD) as potential antiparasitic agents.

81 We investigated whether two common antiparasitics-albendazole (ALB) and metronidazole (MTZ)

82 antiviral, 105 anti-HIV, 959 antifungal, 80 antiparasitic and 185 anticancer peptides.

83 Almost two-thirds of patients had an antiparasitic and 27% had an antibiotic during the study

84 w investigators have reported antibacterial, antiparasitic and anti-cancer activities of the plant.

85 1 gene, whose complement C3-like product has antiparasitic and antibacterial activity.

86 When Giardia-specific tests and antiparasitic and antibiotic prescriptions were examined

87 arkinson's and Alzheimer's, as well as their antiparasitic and antihypertensive properties.

88 to the N1 aromatic ring generally decreases antiparasitic and antimitotic potency, but placement of

89 orters have been implicated in the uptake of antiparasitic and experimental drugs in these and other

90 s, of use in bone resorption therapy, and as antiparasitic and immunotherapeutic agents.

91 Inclusion of antiparasitics and other beneficial interventions in HIV

92 -terminal domain in mediating antibacterial, antiparasitic, and antiinvasive activities, with the C-t

93 iven their potent antibacterial, antifungal, antiparasitic, and antiviral properties, which can be su

94 ntive, antiviral, antibacterial, antifungal, antiparasitic, and neuroprotective effects.

95 ing antibacterial, antiviral, antimicrobial, antiparasitic, and, importantly, antitumor properties.

96 eviously shown to possess anti-inflammatory, antiparasitic, antibacterial and antiviral activities.

97 The antiparasitic, antibiotic and antibiotic-modifying activ

98 antitumor, anti-inflammatory, antimicrobial, antiparasitic, antimutagenic, chemopreventive and chemot

99 ficant antibacterial, antifungal, antiviral, antiparasitic, antitumour, anti-inflammatory, antioxidan

100 apeutically diverse compound which possesses antiparasitic, antiviral and antibacterial properties.

101 activates this broad-spectrum antimicrobial, antiparasitic, antiviral or cytotoxic agent within the i

102 Doramectin is a commercial antiparasitic avermectin analog produced by fermenting a

103 tion is observed in animals treated with the antiparasitic benznidazole.

104 s represent promising, environmentally safer antiparasitic candidates aligned with One Health and Gre

105 Here, we show that these antiparasitic cardenolides can also impose significant c

106 In VL patients, antiparasitic CD4+ T-cell responses are ineffective for

107 zoan parasites are resistant to conventional antiparasitic chemotherapies and the currently available

108 ways provide numerous successful targets for antiparasitic chemotherapy, but the human pathogen Crypt

109 has been advanced as a potential target for antiparasitic chemotherapy.

110 aptopurine and allopurinol, and a target for antiparasitic chemotherapy.

111 mmunosuppressive, antiviral, anticancer, and antiparasitic chemotherapy.

112 The antiparasitic clioquinol (CQ) represents a class of nove

113 the potential of milbemycin oxime (MBO), an antiparasitic compound, as an immunomodulatory agent in

114 using natural variation in concentrations of antiparasitic compounds among plants.

115 Overall, our results suggest that the use of antiparasitic compounds carries substantial costs, which

116 lved medication behaviours, whereby they use antiparasitic compounds from their environment to protec

117 study, we explore the costs of the usage of antiparasitic compounds in monarch butterflies (Danaus p

118 squito-stage of development by incorporating antiparasitic compounds into LLINs.

119 ure-centric approach to support discovery of antiparasitic compounds promises much.

120 represent targets of the avermectin class of antiparasitic compounds, have recently been cloned from

121 ibutes to strategies for the design of novel antiparasitic compounds.

122 al model for rapid, inexpensive screening of antiparasitic compounds.

123 he parasite population through the intake of antiparasitic compounds.

124 ary approach to the development of selective antiparasitic compounds.

125 Mass antiparasitic drug administration programs and other con

126 Niclosamide, an antiparasitic drug approved for human use, has been rece

127 le for why ivermectin, an effective and safe antiparasitic drug at low nanomolar concentrations, beco

128 In this study, we show that the common antiparasitic drug atovaquone inhibits arbovirus replica

129 loroquine, tetracycline and a broad spectrum antiparasitic drug atovaquone.

130 itrichomonas foetus is a rational target for antiparasitic drug design because it is the primary enzy

131 ine proteases are exciting novel targets for antiparasitic drug design.

132 n Toxoplasma gondii is a rational target for antiparasitic drug design.

133 fication and validation of novel targets for antiparasitic drug discovery in veterinary medicine.

134 ng highlights exciting new opportunities for antiparasitic drug discovery resulting from major advanc

135 The approach is especially applicable to antiparasitic drug discovery where the phylogenetic dist

136 ghts the potential of covalent inhibition in antiparasitic drug discovery.

137 ioselective approach to the synthesis of the antiparasitic drug fluralaner (Bravecto, presently sold

138 The antiparasitic drug ivermectin efficiently inhibits the r

139 The antiparasitic drug ivermectin was proposed as a repurpos

140 ubunits confers high-level resistance to the antiparasitic drug ivermectin.

141 ction for T. gondii mutants resistant to the antiparasitic drug monensin, we have isolated a strain t

142 iously, we found that the small molecule and antiparasitic drug nitazoxanide (NTZ) inhibits CU pathwa

143 preventive and therapeutic potentials of the antiparasitic drug Praziquantel as a possible antifibrot

144 We previously reported that the antiparasitic drug pyrimethamine (PYR) inhibits NRF2 in

145 tion of its biosynthesis may provide a novel antiparasitic drug target.

146 eukaryotes, is a potential antimicrobial and antiparasitic drug target.

147 Ivermectin is an FDA-approved broad-spectrum antiparasitic drug that also exhibits antiviral properti

148 ministration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on

149 Diminazene aceturate (DIZE) is an antiparasitic drug that has been reported to exert prote

150 Atovaquone is an antiparasitic drug that selectively inhibits electron tr

151 IVM is an FDA-approved antiparasitic drug that was discovered in the 1970s and

152 rmectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19.

153 Albendazole is a new, broad-spectrum antiparasitic drug, which was approved recently by the F

154 followed by or concurrent with an effective antiparasitic drug, without ineffective antibiotics.

155 g suramin, a century-old, negatively charged antiparasitic drug.

156 r the past 30 years, only few broad-spectrum antiparasitic drugs (mainly topical permethrin and oral

157 At least 564 women received antiparasitic drugs according to a standard protocol.

158 The only two antiparasitic drugs approved for its treatment, benznida

159 nt study demonstrated that combining these 2 antiparasitic drugs improves antiparasitic efficacy.

160 iscovery, facilitating the evaluation of new antiparasitic drugs in vitro and in animals, elucidating

161 Some HIV and antiparasitic drugs might induce diabetes, whereas helmi

162 In 21 studies, efficacy of treatment with antiparasitic drugs ranged from 0 to 100% (35.7% of 269

163 rinary medicine is exploiting the ability of antiparasitic drugs to make vertebrate blood toxic for b

164 bally, this is pushing discovery research of antiparasitic drugs toward new agents endowed with new m

165 ents should be treated with corticosteroids, antiparasitic drugs, and shunting if hydrocephalus is pr

166 ia has been exploited for the development of antiparasitic drugs, especially those used to treat mala

167 bananas, and helminth infections by applying antiparasitic drugs, in two groups of wild black capuchi

168 gram aimed at discovering novel DNA-targeted antiparasitic drugs, the phenylfuran-benzimidazole unfus

169 cult to implement, lagging behind the use of antiparasitic drugs, vaccine development and transmissio

170 e used for the development of more effective antiparasitic drugs.

171 is an overall unmet and urgent need for new antiparasitic drugs.

172 e therefore emerged as promising targets for antiparasitic drugs.

173 eases and the potential of vinyl sulfones as antiparasitic drugs.

174 facilitate the eventual design of selective antiparasitic drugs.

175 ent opportunity for directed design of novel antiparasitic drugs.

176 sistant crops, as well as new antibiotic and antiparasitic drugs.

177 patients are treated with prednisone and/or antiparasitic drugs.

178 have not demonstrated a clinical benefit for antiparasitic drugs.

179 the prospects for using enzyme inhibitors as antiparasitic drugs.

180 ery and development of urgently needed novel antiparasitic drugs.

181 us leishmaniasis disease in combination with antiparasitic drugs.

182 s gradual during malaria and is modulated by antiparasitic drugs.

183 able Giardia-specific diagnostic testing and antiparasitic drugs.

184 Human DHFR was found to fully negate the antiparasitic effect of WR99210, thus demonstrating that

185 ation with artesunate produced an additional antiparasitic effect with a prolonged survival period.

186 l, highlighting the transgenic expression of antiparasitic effector genes, inactivation of host facto

187 In search of additional antiparasitic effector genes, we have generated transgen

188 (IFN)-gamma-producing T cells, which induce antiparasitic effector mechanisms in infected cells, as

189 h a fundamental role in the amplification of antiparasitic effector mechanisms, provide a useful way

190 it its activity in vitro, and produce strong antiparasitic effects in the cultured TC cells.

191 e that we previously found to produce potent antiparasitic effects in Trypanosomatidae.

192 ase of T. spiralis infection and to test the antiparasitic effects of such antibodies.

193 ising results concerning the selectivity and antiparasitic effects.

194 tentially neglecting plants with the biggest antiparasitic effects.

195 etween high ASOX plasma levels and increased antiparasitic efficacy in patients with parenchymal NCC.

196 bark extracts varied markedly from 0 to 100% antiparasitic efficacy, owing to tree species, extractio

197 therapy may be associated with an increased antiparasitic efficacy.

198 mbining these 2 antiparasitic drugs improves antiparasitic efficacy.

199 Fxn levels, including the azole bifonazole, antiparasitic fipronil, antitumor compound dibenzoylmeth

200 s beyond IgE-mediated allergic responses and antiparasitic functions.

201 ma9Vdelta2 T cells that in turn exert remote antiparasitic functions.

202 generate transgenic mosquitoes that express antiparasitic genes in their midgut epithelium, thus ren

203 To determine what topological changes antiparasitic heterocyclic dications can have on kinetop

204 host-nematode interactions and uncover host antiparasitic immune reactions.

205 IgE antibodies mediate antiparasitic immune responses and the inflammatory reac

206 IgE antibodies are key mediators of antiparasitic immune responses, but their potential for

207 from VL patients that can be used to improve antiparasitic immune responses.

208 ovement of drug-treatment protocols to boost antiparasitic immunity are critical for malaria eliminat

209 tment to improve clinical outcomes and boost antiparasitic immunity in clinical malaria.

210 an reduce inflammatory responses and enhance antiparasitic immunity in malaria-naive volunteers inocu

211 red for the establishment and maintenance of antiparasitic immunity in the liver, as well as for immu

212 eloping theme in field studies investigating antiparasitic immunity is the emergence, establishment,

213 s, including MHC expression, senescence, and antiparasitic immunity, and shifted the transcriptional

214 therapeutic potential of IL-2 for improving antiparasitic immunity.

215 gulatory barriers that hinder development of antiparasitic immunity.

216 o modulate CD4+ T cell functions and improve antiparasitic immunity.

217 s used as antiviral, antibiotic, antifungal, antiparasitic, immunosuppressive, and antitumor drugs.

218 sphorylation constitutes a viable target for antiparasitic intervention.

219 d are crucial to identifying new targets for antiparasitic interventions.

220 his protein kinase as a promising target for antiparasitic interventions.

221 e future approaches to expand the horizon of antiparasitic interventions.

222 e paradigm for understanding the fundamental antiparasitic mechanisms of DOX and suggest repurposing

223 ice, indicating that distinct organ-specific antiparasitic mechanisms were involved in control of L.

224 Surprisingly, the antiparasitic nucleosides AraT, AraC, and IDC are not su

225 ve been few investigations of the effects of antiparasitics on the gut microbiome in the absence of p

226 ), and with previous antibiotic (P = .02) or antiparasitic(P = .04) use.

227 chains characteristic of the lipid tails of antiparasitic peptides to the p-position of anisomycin g

228 Flowers that produce antiparasitic phytochemicals, including thymol, could po

229 tory effects on T. cruzi CYP51 activity, and antiparasitic potencies of a new set of beta-phenyl imid

230 ouping 404 non-cytotoxic compounds with high antiparasitic potency, drug-likeness, structural diversi

231 The antiparasitic potential of plants could offer a vital so

232 dult sequences most frequently began with an antiparasitic prescription.

233 set, we identified an aminoxadiazole with an antiparasitic profile comparable with artemisinin (1), w

234 y new chemotypes that could deliver the same antiparasitic profile.

235 Given its potent antiparasitic properties and its ease of synthesis, comp

236 iproliferative, antivascular, antiviral, and antiparasitic properties have attracted the attention of

237 The antiparasitic properties of azoles are derived from inhi

238 Heterocyclic diamidines are compounds with antiparasitic properties that target the minor groove of

239 m biological activities, including potential antiparasitic properties.

240 compounds with optimized pharmacological and antiparasitic properties.

241 36; 95% C.I. 1.02-1.81), not receiving early antiparasitic re-treatment (RR: 1.45; 1.08-1.93), or com

242 essential immune effector molecule mediating antiparasitic resistance.

243 ate type I IFN signaling to evade epithelial antiparasitic response.

244 in controlling infection intensity-dependent antiparasitic responses.

245 low toxicity in fibroblasts in vitro, while antiparasitic results against Trypnosoma cruzi, Leishman

246 .36; 95% CI, 1.02-1.81), not receiving early antiparasitic retreatment (RR, 1.45; 95% CI, 1.08-1.93),

247 provide insights for the development of new antiparasitic strategies.

248 feasibility of targeting host proteins as an antiparasitic strategy, mammalian PKC inhibitors demonst

249 ) stores by the enhancer may be an effective antiparasitic strategy.

250 his study provides the first insight on this antiparasitic target enzyme essential for survival of th

251 diverse parasitic nematodes, suggesting the antiparasitic target potential of SBT-1.

252 smodium and is not found in humans, it is an antiparasitic target.

253 r structural and functional studies of novel antiparasitic targets.

254 hosphate dehydrogenase as the most selective antiparasitic targets.

255 ns, they are now emerging as novel potential antiparasitic targets.

256 with more effective, affordable, and benign antiparasitic therapeutics.

257 enetic processes will aid the development of antiparasitic therapeutics.

258 used as alternatives or adjuncts to current antiparasitic therapies.

259 therapy, there is no consistently effective antiparasitic therapy for cryptosporidiosis in AIDS.

260 With appropriate use of antiparasitic therapy, the visual prognosis for patients

261 t for these drugs and a potential target for antiparasitic therapy.

262 rt and is, therefore, a potential target for antiparasitic therapy.

263 ge can be prevented with early diagnosis and antiparasitic therapy.

264 To detect specific monoclonal antiparasitic (Toxocara - IgG and Toxoplasma gondii IgM

265 All of them completed antiparasitic treatment and underwent follow-up brain MR

266 iduals early in the course of infection when antiparasitic treatment can reduce the risk of disease p

267 of the cysts that resolved six months after antiparasitic treatment ended up in a residual calcifica

268 The efficacy of current antiparasitic treatment for cerebral Taenia solium cysti

269 These findings suggest that, in CCPs, antiparasitic treatment improved the quality of Ag-speci

270 Antiparasitic treatment is controversial as to its indic

271 nt study was to analyze the early effects of antiparasitic treatment on CD8(+) T cells from CCPs with

272 es, including all the villages in which mass antiparasitic treatment plus vaccination was implemented

273 enchymal NCC from three randomized trials of antiparasitic treatment was assessed to determine what p

274 ly to have ocular involvement (P = .043) and antiparasitic treatment was associated with less ocular

275 tients with parenchymal NCC from 3 trials of antiparasitic treatment were assessed to determine what

276 Antiparasitic treatment with benznidazole does not preve

277 cal markers to evaluate the effectiveness of antiparasitic treatment, and little is known about the e

278 that involved screening of humans and pigs, antiparasitic treatment, prevention education, and pig r

279 Sub-Saharan Africa, where, despite effective antiparasitic treatment, survivors develop long-term neu

280 ately 38% of parenchymal cysts calcify after antiparasitic treatment.

281 other group members were not affected by the antiparasitic treatment.

282 sioned, but it did not vary according to the antiparasitic treatment.

283 omarkers for monitoring the effectiveness of antiparasitic treatment.

284 health worldwide, and off-target effects of antiparasitic treatments may be an additional obstacle t

285 differentiation in the context of protective antiparasitic type 2 immunity.

286 A new generation of antiparasitic vaccines will be needed.

287 gh potency of piritrexim (PTX) with the high antiparasitic vs mammalian selectivity of trimethoprim (

288 TMFS method to discover that mebendazole, an antiparasitic with recently discovered and unexpected an